Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract -: A randomized, placebo-controlled, double-blind trial

被引:109
|
作者
de La Cal, MA
Cerdá, E
García-Hierro, P
van Saene, HKF
Gómez-Santos, D
Negro, E
Lorente, JA
机构
[1] Univ Madrid, Hosp Getafe, Dept Crit Care Med, Madrid 28905, Spain
[2] Univ Madrid, Hosp Getafe, Dept Med Microbiol, Madrid 28905, Spain
[3] Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England
[4] Royal Liverpool Childrens NHS Trust, Liverpool, Merseyside, England
[5] Univ Madrid, Hosp Getafe, Dept Radiol, Madrid 28905, Spain
[6] Univ Madrid, Hosp Getafe, Dept Pharm, Madrid 28905, Spain
关键词
D O I
10.1097/01.sla.0000154148.58154.d5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To evaluate whether selective digestive decontamination (SDD) reduces mortality from any cause, and the incidence of pneumonia among patients with severe burns. Summary Background Data: SDD is a prophylactic strategy to reduce infectious morbidity and mortality in critically ill patients. Two meta-analyses and a recent randomized controlled trial demonstrated a mortality reduction varying between 20% and 40%. But this technique has never been properly evaluated in severely burned patients. Methods: The design of this single-center trial was randomized, double blind, placebo controlled. Patients with burns greater than or equal to20% of total body surface and/or suspected inhalation injury were enrolled and assigned to receive SDD or placebo for the total duration of treatment in the burn intensive care unit (ICU). Results: One hundred seventeen patients were randomized and 107 were analyzed (53 in the SDD group and 54 in the placebo group). The ICU mortality was 27.8% in the placebo group and 9.4% in the SDD group in the burn ICU. Treatment with SDD was associated with a significant reduction in mortality both in the burn ICU (risk ratio 0.25; 95% CI 0.08 to 0.76) and in the hospital (risk ratio 0.28; 95% CI 0.10 to 0.80), following adjustment for predicted mortality. The incidence of pneumonia was significantly higher in the placebo group: 30.8 and 17.0 pneumonias per 1000 ventilation days (P = 0.03) in placebo and SDD group, respectively. Conclusions: Treatment with SDD reduces mortality and pneumonia incidence in patients with severe burns.
引用
收藏
页码:424 / 430
页数:7
相关论文
共 50 条
  • [21] Selective digestive tract decontamination in critically ill patients
    Silvestri, Luciano
    van Saene, Hendrick K. F.
    Petros, Andy J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1113 - 1129
  • [22] Selective decontamination of the digestive tract to prevent postoperative infection: A randomized placebo-controlled trial in liver transplant patients
    Zwaveling, JH
    Maring, JK
    Klompmaker, IJ
    Haagsma, EB
    Bottema, JT
    Laseur, M
    Winter, HLJ
    van Enckevort, PJ
    TenVergert, EM
    Metselaar, HJ
    Bruining, HA
    Slooff, MJH
    CRITICAL CARE MEDICINE, 2002, 30 (06) : 1204 - 1209
  • [23] Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation A Randomized Clinical Trial
    Myburgh, John A.
    Seppelt, Ian M.
    Goodman, Fiona
    Billot, Laurent
    Correa, Maryam
    Davis, Joshua S.
    Gordon, Anthony C.
    Hammond, Naomi E.
    Iredell, Jon
    Li, Qiang
    Micallef, Sharon
    Miller, Jennene
    Mysore, Jayanthi
    Taylor, Colman
    Young, Paul J.
    Cuthbertson, Brian H.
    Finfer, Simon R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (19): : 1911 - 1921
  • [24] Prevention of Nosocomial Infections in Critically Ill Patients With Lactoferrin: A Randomized, Double-Blind, Placebo-Controlled Study
    Muscedere, John
    Maslove, David M.
    Boyd, J. Gordon
    O'Callaghan, Nicole
    Sibley, Stephanie
    Reynolds, Steven
    Albert, Martin
    Hall, Richard
    Jiang, Xuran
    Day, Andrew G.
    Jones, Gwyneth
    Lamontagne, Francois
    CRITICAL CARE MEDICINE, 2018, 46 (09) : 1450 - 1456
  • [25] Microbiology for the critically ill patient receiving selective decontamination of the digestive tract
    Silvestri, L
    Fontana, F
    Van Saene, HKF
    Petros, AJ
    INFECTIONS IN THE CRITICALLY ILL: AN ONGOING CHALLENGE, 2001, : 81 - 93
  • [26] Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients
    Pelz, RK
    Hendrix, CW
    Swoboda, SM
    Diener-West, M
    Merz, WG
    Hammond, J
    Lipsett, PA
    ANNALS OF SURGERY, 2001, 233 (04) : 542 - 548
  • [27] Efficacy of erythropoietin (R-HuEPO) in the critically ill patient: A randomized, double-blind, placebo-controlled trial
    Gettinger, A
    Corwin, HL
    Pearl, RG
    ANESTHESIOLOGY, 2002, 97 (03) : B11 - B11
  • [28] The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: A prospective, randomized, double-blind, placebo-controlled trial
    Crimi, E
    Liguori, A
    Condorelli, M
    Cioffi, M
    Astuto, M
    Bontempo, P
    Pignalosa, O
    Vietri, MT
    Molinari, AM
    Sica, V
    Della Corte, F
    Napoli, C
    ANESTHESIA AND ANALGESIA, 2004, 99 (03): : 857 - 863
  • [29] Laxation of critically ill patients with lactulose or polyethylene glycol: A two-center randomized, double-blind, placebo-controlled trial
    van der Spoel, Johan I.
    Straaten, Heleen M. Oudernans-van
    Kuiper, Michael A.
    van Roon, Eric N.
    Zandstra, Durk F.
    van der Voort, Peter H. J.
    CRITICAL CARE MEDICINE, 2007, 35 (12) : 2726 - 2731
  • [30] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270